An observational study in Cardiogenic Shock, Myocardial Infarction (MI) and Fulminant Myocarditis, sponsored by University Hospital, Basel, Switzerland. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by University Hospital, Basel, Switzerland · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This regulation defines the purpose, the operational processes, and the organization of the registry BEAT-SHOCK (Basel Evaluation of Acute Therapy in cardiogenic SHOCK). It describes the requirements for collecting, storing, processing, managing and sharing health-related registry data.
297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
This study's planned enrollment of 8,000 is above the median of 200 across 156 observational studies indexed under Shock, Cardiogenic.
Browse Shock, Cardiogenic studies →University Hospital, Basel, Switzerland is the lead sponsor of 990 studies on the registry; 189 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients who are treated at the University Hospital Basel and are diagnosed with cardiogenic shock, irrespective of underlying etiology or therapeutic strategy. The registry includes a wide range of cardiogenic shock etiologies, including:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is a health data registry.
In-Hospital all-cause mortality occurring before discharge from the participating study centre
In-hospital all-cause mortality is defined as death occurring before discharge from the participating study centre. Deaths occurring after transfer to an external hospital are not counted as in-hospital deaths, but are captured through follow-up for 30-day and 90-day mortality.
Time frame: 10 years
30-day and 90-day all-cause Mortality
30-day and 90-day all-cause mortality occuring after discharge from the participating study centre.
Time frame: 30, 90 days
Need for organ support at any time during hospitalization
The need for organ support at any time during hospitalization (including renal replacement therapy, mechanical circulation support irrespective of type, and vasoactive or inotropic therapy)
Time frame: 30, 60, 360 days
Acute kidney injury (AKI) within 36 hours after index diagnosis of cardiogenic shock/index presentation
Occurence of AKI (defined as an increase in serum creatinine of at least 26 µmol/L (0.3 mg/dL)
Time frame: Within 36 hours after index diagnosis of cardiogenic shock/ index presentation.
Plan to share: Undecided — Not necessary, only data registry.
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Oct 2035, 120 months after the start.
Of 79 non-industry observational studies under Shock, Cardiogenic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 19. This study's planned 120 months is above that.
Counting every sponsor, half of 85 studies reached it within 45 months; a quarter within 24.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Basel, Switzerland →